Ribosome Inactivating Proteins from Plants: Biological Properties and their Use in Experimental Therapy

  • Lucía Citores
  • Rosario Iglesias
  • José Miguel Ferreras


Ribosome-inactivating proteins (RIPs) are 28 S rRNA N-glycosidases isolated mainly from plants that irreversibly inactivate ribosomes, thereby impairing protein synthesis. In recent years, polynucleotide:adenosine N-glycosidase activity and induction of apoptosis have been reported and may have a particular significance. There are two classes of RIPs: type 1 RIPs, consisting of single-chain proteins, and type 2 RIPs, consisting of an A chain with RIP properties covalently linked to a B chain with lectin properties. Type 2 RIPs may be very toxic or non toxic, whereas type 1 RIPs are always non-toxic. Due to the diverse activities of RIPs, research has been conducted to investigate their use as antiviral and antitumor agents or as the toxic part of conjugates. Conjugates consist of a targeting portion such as an antibody, a lectin or a growth factor linked to a toxic portion. RIPs have been used as the toxic portion in conjugates that have been tested in several experimental therapies against various malignancies. Although some important disadvantages still need to be improved, recent clinical trials encourage the use of these conjugates as efficacious agents in the treatment of cancer and other diseases.


Protein Synthesis Inhibition Oral Squamous Cell Carcinoma Cell Disulphide Bridge Vascular Leak Syndrome Sugar Binding Site 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



This work was supported by grants FISPI04/1279 to J.M.F. and BIO39/VA42/10 to L.C. We thank Judy Callaghan (Monash University, Melbourne, Australia) for correcting the manuscript.


  1. 1.
    Barbieri L, Battelli MG, Stirpe F (1993) Ribosome-inactivating proteins from plants. Biochim Biophys Acta 1154:237–282PubMedCrossRefGoogle Scholar
  2. 2.
    Stirpe F, Barbieri L (1986) Ribosome-inactivating proteins up to date. FEBS Lett 195:1–8PubMedCrossRefGoogle Scholar
  3. 3.
    Girbes T, Ferreras JM, Arias FJ, Stirpe F (2004) Description, distribution, activity and phylogenetic relationship of ribosome-inactivating proteins in plants, fungi and bacteria. Mini Rev Med Chem 4:461–476PubMedCrossRefGoogle Scholar
  4. 4.
    Obrig TG (1997) Shiga toxin mode of action in E. coli O157:H7 disease. Front Biosci 2:d635–d642PubMedGoogle Scholar
  5. 5.
    Barbieri L, Valbonesi P, Bonora E, Gorini P, Bolognesi A, Stirpe F (1997) Polynucleotide: adenosine glycosidase activity of ribosome-inactivating proteins: effect on DNA, RNA and poly(A). Nucleic Acids Res 25:518–522PubMedCrossRefGoogle Scholar
  6. 6.
    Polito L, Bortolotti M, Farini V, Battelli MG, Barbieri L, Bolognesi A (2009) Saporin induces multiple death pathways in lymphoma cells with different intensity and timing as compared to ricin. Int J Biochem Cell Biol 41:1055–1061PubMedCrossRefGoogle Scholar
  7. 7.
    Ferreras JM, Citores L, Iglesias R, Jimenez P, Girbes T (2011) Use of ribosome-inactivating proteins from Sambucus for the construction of immunotoxins and conjugates for cancer therapy. Toxins (Basel) 3:420–441CrossRefGoogle Scholar
  8. 8.
    Ferreras JM, Citores L, Iglesias R, Jiménez P, Girbés T (2010) Sambucus ribosome-inactivating proteins and lectins. In: Lord JM, Hartley MR (eds) Toxic plant proteins-series plant cell monographs, vol 18. Springer, Berlin, pp 107–131Google Scholar
  9. 9.
    Mak AN, Wong YT, An YJ, Cha SS, Sze KH, Au SW, Wong KB, Shaw PC (2007) Structure-function study of maize ribosome-inactivating protein: implications for the internal inactivation region and the sole glutamate in the active site. Nucleic Acids Res 35:6259–6267PubMedCrossRefGoogle Scholar
  10. 10.
    Wang HX, Ng TB (2001) Isolation of pleuturegin, a novel ribosome-inactivating protein from fresh sclerotia of the edible mushroom Pleurotus tuber-regium. Biochem Biophys Res Commun 288:718–721PubMedCrossRefGoogle Scholar
  11. 11.
    Liu RS, Yang JH, Liu WY (2002) Isolation and enzymatic characterization of lamjapin, the first ribosome-inactivating protein from cryptogamic algal plant (Laminaria japonica A). Eur J Biochem 269:4746–4752PubMedCrossRefGoogle Scholar
  12. 12.
    Endo Y, Tsurugi K (1988) The RNA N-glycosidase activity of ricin A-chain. The characteristics of the enzymatic activity of ricin A-chain with ribosomes and with rRNA. J Biol Chem 263:8735–8739PubMedGoogle Scholar
  13. 13.
    Shi X, Khade PK, Sanbonmatsu KY, Joseph S (2012) Functional role of the sarcin-ricin loop of the 23S rRNA in the elongation cycle of protein synthesis. J Mol Biol 419:125–138PubMedCrossRefGoogle Scholar
  14. 14.
    Barbieri L, Ferreras JM, Barraco A, Ricci P, Stirpe F (1992) Some ribosome-inactivating proteins depurinate ribosomal RNA at multiple sites. Biochem J 286(Pt 1):1–4PubMedGoogle Scholar
  15. 15.
    Barbieri L, Brigotti M, Perocco P, Carnicelli D, Ciani M, Mercatali L, Stirpe F (2003) Ribosome-inactivating proteins depurinate poly(ADP-ribosyl)ated poly(ADP-ribose) polymerase and have transforming activity for 3T3 fibroblasts. FEBS Lett 538:178–182PubMedCrossRefGoogle Scholar
  16. 16.
    Sestili P, Alfieri R, Carnicelli D, Martinelli C, Barbieri L, Stirpe F, Bonelli M, Petronini PG, Brigotti M (2005) Shiga toxin 1 and ricin inhibit the repair of H2O2-induced DNA single strand breaks in cultured mammalian cells. DNA Repair (Amst) 4:271–277CrossRefGoogle Scholar
  17. 17.
    Sikriwal D, Batra JK (2010) Ribosome inactivating proteins and apoptosis. In: Lord JM, Hartley MR (eds) Toxic plant proteins-series plant cell monographs, vol 18. Springer, Berlin pp 167–189Google Scholar
  18. 18.
    Das MK, Sharma RS, Mishra V (2012) Induction of apoptosis by ribosome inactivating proteins: importance of N-glycosidase activity. Appl Biochem Biotechnol 166:1552–1561PubMedCrossRefGoogle Scholar
  19. 19.
    Pascal JM, Day PJ, Monzingo AF, Ernst SR, Robertus JD, Iglesias R, Perez Y, Ferreras JM, Citores L, Girbes T (2001) 2.8-A crystal structure of a nontoxic type-II ribosome-inactivating protein, ebulin l. Proteins 43:319–326PubMedCrossRefGoogle Scholar
  20. 20.
    van Deurs B, Sandvig K, Petersen OW, Olsnes S, Simons K, Griffiths G (1988) Estimation of the amount of internalized ricin that reaches the trans-Golgi network. J Cell Biol 106:253–267PubMedCrossRefGoogle Scholar
  21. 21.
    Lord JM, Spooner RA (2011) Ricin trafficking in plant and mammalian cells. Toxins (Basel) 3:787–801CrossRefGoogle Scholar
  22. 22.
    Battelli MG, Musiani S, Buonamici L, Santi S, Riccio M, Maraldi NM, Girbes T, Stirpe F (2004) Interaction of volkensin with HeLa cells: binding, uptake, intracellular localization, degradation and exocytosis. Cell Mol Life Sci 61:1975–1984PubMedCrossRefGoogle Scholar
  23. 23.
    Vago R, Marsden CJ, Lord JM, Ippoliti R, Flavell DJ, Flavell SU, Ceriotti A, Fabbrini MS (2005) Saporin and ricin A chain follow different intracellular routes to enter the cytosol of intoxicated cells. FEBS J 272:4983–4995PubMedCrossRefGoogle Scholar
  24. 24.
    Reisler RB, Smith LA (2012) The need for continued development of ricin countermeasures. Adv Prev Med 2012:149737PubMedGoogle Scholar
  25. 25.
    Lin JY, Tserng KY, Chen CC, Lin LT, Tung TC (1970) Abrin and ricin: new anti-tumour substances. Nature 227:292–293PubMedCrossRefGoogle Scholar
  26. 26.
    Fu LL, Zhou CC, Yao S, Yu JY, Liu B, Bao JK (2011) Plant lectins: targeting programmed cell death pathways as antitumor agents. Int J Biochem Cell Biol 43:1442–1449PubMedCrossRefGoogle Scholar
  27. 27.
    Pryme IF, Bardocz S, Pusztai A, Ewen SW (2006) Suppression of growth of tumour cell lines in vitro and tumours in vivo by mistletoe lectins. Histol Histopathol 21:285–299PubMedGoogle Scholar
  28. 28.
    Zwierzina H, Bergmann L, Fiebig H, Aamdal S, Schoffski P, Witthohn K, Lentzen H (2011) The preclinical and clinical activity of aviscumine: a potential anticancer drug. Eur J Cancer 47:1450–1457PubMedCrossRefGoogle Scholar
  29. 29.
    Voss C, Eyol E, Frank M, von der Lieth CW, Berger MR (2006) Identification and characterization of riproximin, a new type II ribosome-inactivating protein with antineoplastic activity from Ximenia americana. FASEB J 20:1194–1196PubMedCrossRefGoogle Scholar
  30. 30.
    Shaw PC, Lee KM, Wong KB (2005) Recent advances in trichosanthin, a ribosome-inactivating protein with multiple pharmacological properties. Toxicon 45:683–689PubMedCrossRefGoogle Scholar
  31. 31.
    Fang EF, Ng TB (2011) Bitter gourd (Momordica charantia) is a cornucopia of health: a review of its credited antidiabetic, anti-HIV, and antitumor properties. Curr Mol Med 11:417–436PubMedCrossRefGoogle Scholar
  32. 32.
    Liu L, Wang R, He W, He F, Huang G (2010) Cloning and soluble expression of mature alpha-luffin from Luffa cylindrica and its antitumor activities in vitro. Acta Biochim Biophys Sin (Shanghai) 42:585–592CrossRefGoogle Scholar
  33. 33.
    Becker N, Benhar I (2012) Antibody-based immunotoxins for the treatment of cancer. Antibodies 1:39–69CrossRefGoogle Scholar
  34. 34.
    Polito L, Bortolotti M, Pedrazzi M, Bolognesi A (2011) Immunotoxins and other conjugates containing saporin-s6 for cancer therapy. Toxins (Basel) 3:697–720CrossRefGoogle Scholar
  35. 35.
    de Virgilio M, Lombardi A, Caliandro R, Fabbrini MS (2010) Ribosome-inactivating proteins: from plant defense to tumor attack. Toxins (Basel) 2:2699–2737CrossRefGoogle Scholar
  36. 36.
    Dosio F, Brusa P, Cattel L (2011) Immunotoxins and anticancer drug conjugate assemblies: the role of the linkage between components. Toxins (Basel) 3:848–883CrossRefGoogle Scholar
  37. 37.
    Madhumathi J, Verma RS (2012) Therapeutic targets and recent advances in protein immunotoxins. Curr Opin Microbiol 15:300–309PubMedCrossRefGoogle Scholar
  38. 38.
    Gensini GF, Conti AA, Lippi D (2007) The contributions of Paul Ehrlich to infectious disease. J Infect 54:221–224PubMedCrossRefGoogle Scholar
  39. 39.
    Youle RJ, Neville DM Jr (1980) Anti-Thy 1.2 monoclonal antibody linked to ricin is a potent cell-type-specific toxin. Proc Natl Acad Sci U S A 77:5483–5486PubMedCrossRefGoogle Scholar
  40. 40.
    Filipovich AH, Vallera DA, Youle RJ, Quinones RR, Neville DM Jr, Kersey JH (1984) Ex-vivo treatment of donor bone marrow with anti-T-cell immunotoxins for prevention of graft-versus-host disease. Lancet 1:469–472PubMedCrossRefGoogle Scholar
  41. 41.
    Cao Y, Marks JD, Huang Q, Rudnick SI, Xiong C, Hittelman WN, Wen X, Marks JW, Cheung LH, Boland K, Li C, Adams GP, Rosenblum MG (2012) Single-chain antibody-based immunotoxins targeting Her2/neu: design optimization and impact of affinity on antitumor efficacy and off-target toxicity. Mol Cancer Ther 11:143–153PubMedCrossRefGoogle Scholar
  42. 42.
    Yoon DJ, Liu CT, Quinlan DS, Nafisi PM, Kamei DT (2011) Intracellular trafficking considerations in the development of natural ligand-drug molecular conjugates for cancer. Ann Biomed Eng 39:1235–1251PubMedCrossRefGoogle Scholar
  43. 43.
    Daniels TR, Delgado T, Helguera G, Penichet ML (2006) The transferrin receptor part II: targeted delivery of therapeutic agents into cancer cells. Clin Immunol 121:159–176PubMedCrossRefGoogle Scholar
  44. 44.
    Heisler I, Sutherland M, Bachran C, Hebestreit P, Schnitger A, Melzig MF, Fuchs H (2005) Combined application of saponin and chimeric toxins drastically enhances the targeted cytotoxicity on tumor cells. J Control Release 106:123–137PubMedCrossRefGoogle Scholar
  45. 45.
    Lappi DA, Ying W, Barthelemy I, Martineau D, Prieto I, Benatti L, Soria M, Baird A (1994) Expression and activities of a recombinant basic fibroblast growth factor-saporin fusion protein. J Biol Chem 269:12552–12558PubMedGoogle Scholar
  46. 46.
    Davol P, Beitz JG, Mohler M, Ying W, Cook J, Lappi DA, Frackelton AR Jr (1995) Saporin toxins directed to basic fibroblast growth factor receptors effectively target human ovarian teratocarcinoma in an animal model. Cancer 76:79–85PubMedCrossRefGoogle Scholar
  47. 47.
    Smagur A, Boyko MM, Biront NV, Cichon T, Szala S (2009) Chimeric protein ABRaA-VEGF121 is cytotoxic towards VEGFR-2-expressing PAE cells and inhibits B16–F10 melanoma growth. Acta Biochim Pol 56:115–124PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2013

Authors and Affiliations

  • Lucía Citores
    • 1
  • Rosario Iglesias
    • 1
  • José Miguel Ferreras
    • 1
  1. 1.Department of Biochemistry and Molecular Biology and PhysiologyFaculty of Sciences, University of ValladolidValladolidSpain

Personalised recommendations